Ampersand 2018 Limited Partnership - 20 Jan 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Reporting relationship: 10%+ Owner
Issuer ticker: IDXG
Reported as of: 20 Jan 2026
Net transaction value: +$28,000,000
SEC form: 4
Accepted by SEC: 04 Feb 2026, 18:46:14 UTC
Prior SEC filing: 15 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Dana L. Niles By: Dana L. Niles, Chief Operating Officer of AMP-18 MC LLC

Key filing fact

Ampersand 2018 Limited Partnership filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 04 Feb 2026.

Key facts

This page summarizes Ampersand 2018 Limited Partnership's Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 18:46.

Change

Previous filing in this sequence was filed on 15 Oct 2024.
Current net transaction value: +$28,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001734267 Primary reporting owner

Ampersand 2018 Limited Partnership

Relationship: 10%+ Owner
Address: C/O INTERPACE BIOSCIENCES, INC., WATERVIEW PLAZA, SUITE 310 2001 ROUTE 46, PARSIPPANY
Signature: /s/ Dana L. Niles By: Dana L. Niles, Chief Operating Officer of AMP-18 MC LLC
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXG transaction

Common Stock

Conversion of derivative security

Transaction value: $28,000,000
Shares: +13,861,386
Change %
Price: $2.02
Shares after: 13,861,386
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXG transaction Derivative

Series C Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -28,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,861,386
Exercise price: $2.02
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On January 20, 2026, 28,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 13,861,386 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

Footnote F2

The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

Footnote F3

These securities are held of record by Ampersand 2018 Limited Partnership (the "Investor"). AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

Footnote F4

Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F5

The Series C Preferred Shares had no expiration date.